Clinical Trial Update: A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer [Phase 4]

View source ↗

Summary

Phase 4 open-label crossover study in men with advanced prostate cancer evaluating whether switching among Lupron, Eligard, and Zoladex maintains testosterone s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Eligard (leuprolide acetate)
• Lupron (leuprolide)
• Zoladex (goserelin)

Snippet

Sponsor: San Bernardino Urological Associates Medical Group Inc | Conditions: Cancer of Prostate | Phase 4 | Status: COMPLETED